R2 REVLIMID/RITUXIMAB
REGISTEREDCombined Mark
Never miss important updates for R2 REVLIMID/RITUXIMAB
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach
Ownership
CC
Address
Summit, NJ 07901
Critical Dates
First Use Date
May 28, 2019
Filing Date
Oct 15, 2019
Registration Date
Jun 9, 2020
Mark Descriptions
Goods
Class 5
Pharmaceutical preparations for the treatment of certain cancers; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all the aforementioned goods being comprised in part of rituximab...
Services
Class 44
Pharmaceutical preparations for the treatment of certain cancers; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all the aforementioned goods being comprised in part of rituximab...
Mark Elements
Text Mark
R2 REVLIMID/RITUXIMAB
Category
Trademark
Standard Characters
No
Color Claim
Yes
Color Details
The color(s) blue, black and yellow is/are claimed as a feature of the mark.
Design Search Codes
261701
261706
Trademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
No documents found for this trademark.